Curing Atrial Fibrillation: A novel ‘EndoXi’ approach

Atrial Fibrillation (AF) caused by errors in the electrical signals controlling heartbeat, incidence ~60M worldwide affects 1 in 4 people over 40 at some point in their lifetime. US/EU prevalence 4.6M, projected \>12M by 2050\.

AF cost the NHS up to £2548M in 2020 (Eur Heart J Qual Care Clin Outcomes, 2022, based on UK population forecasts and prior published data); i.e. 1.6%x NHS expenditure, mostly primary admissions (60%). Total direct costs will increase to 4.27%x NHS expenditure, by 2040\.

EndoXi is the world's first catheter for hybrid ablation, conceived and developed to improve the methodology of ablation. It enables Electrophysiologists to deliver precise lesion sets on endocardial and epicardial surfaces in a single procedure compared to alternatives that focus on one or the other or require two separate surgeries. NHS cost will be reduced substantially if hospitalizations can be avoided or reduced: EndoXi enables endocardial and epicardial ablation to be performed at lower cost with reduced hospitalisation compared to current practices.